StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)
by Renee Jackson · The Cerbat GemStockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Down 8.4 %
NASDAQ:AKTX opened at $1.09 on Thursday. Akari Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.40. The stock’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.60.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Recommended Stories
- Five stocks we like better than Akari Therapeutics
- Top Stocks Investing in 5G Technology
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Are Penny Stocks a Good Fit for Your Portfolio?
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?